🚀 VC round data is live in beta, check it out!
Aarti Pharmalabs Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aarti Pharmalabs and similar public comparables like Alkaloid, Zentiva, Guizhou Sanli, Eton Pharmaceuticals and more.
Aarti Pharmalabs Overview
About Aarti Pharmalabs
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
Founded
2019
HQ
Employees
2.2K
Website
Financials (FY)
EV
$744M
Aarti Pharmalabs Financials
Aarti Pharmalabs reported last fiscal year revenue of $223M and EBITDA of $51M.
In the same fiscal year, Aarti Pharmalabs generated $93M in gross profit, $51M in EBITDA, and $29M in net income.
Aarti Pharmalabs P&L
In the most recent fiscal year, Aarti Pharmalabs reported revenue of $223M and EBITDA of $51M.
Aarti Pharmalabs expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $223M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $93M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 42% | XXX | XXX | XXX |
| EBITDA | — | XXX | $51M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 18% | XXX | XXX | XXX |
| Net Profit | — | XXX | $29M | XXX | XXX | XXX |
| Net Margin | — | XXX | 13% | XXX | XXX | XXX |
| Net Debt | — | — | $43M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aarti Pharmalabs Stock Performance
Aarti Pharmalabs has current market cap of $679M, and enterprise value of $744M.
Market Cap Evolution
Aarti Pharmalabs' stock price is $7.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $744M | $679M | -0.7% | XXX | XXX | XXX | $0.32 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAarti Pharmalabs Valuation Multiples
Aarti Pharmalabs trades at 3.3x EV/Revenue multiple, and 14.6x EV/EBITDA.
Aarti Pharmalabs Financial Valuation Multiples
As of April 17, 2026, Aarti Pharmalabs has market cap of $679M and EV of $744M.
Equity research analysts estimate Aarti Pharmalabs' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aarti Pharmalabs has a P/E ratio of 23.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $679M | XXX | $679M | XXX | XXX | XXX |
| EV (current) | $744M | XXX | $744M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 14.6x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 18.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.0x | XXX | XXX | XXX |
| P/E | — | XXX | 23.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (61.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aarti Pharmalabs Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aarti Pharmalabs Margins & Growth Rates
Aarti Pharmalabs' revenue in the last fiscal year grew by 3%.
Aarti Pharmalabs' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Aarti Pharmalabs Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aarti Pharmalabs Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aarti Pharmalabs | XXX | XXX | XXX | XXX | XXX | XXX |
| Alkaloid | XXX | XXX | XXX | XXX | XXX | XXX |
| Zentiva | XXX | XXX | XXX | XXX | XXX | XXX |
| Guizhou Sanli | XXX | XXX | XXX | XXX | XXX | XXX |
| Eton Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Prime Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aarti Pharmalabs M&A Activity
Aarti Pharmalabs acquired XXX companies to date.
Last acquisition by Aarti Pharmalabs was on XXXXXXXX, XXXXX. Aarti Pharmalabs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aarti Pharmalabs
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAarti Pharmalabs Investment Activity
Aarti Pharmalabs invested in XXX companies to date.
Aarti Pharmalabs made its latest investment on XXXXXXXX, XXXXX. Aarti Pharmalabs invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aarti Pharmalabs
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aarti Pharmalabs
| When was Aarti Pharmalabs founded? | Aarti Pharmalabs was founded in 2019. |
| Where is Aarti Pharmalabs headquartered? | Aarti Pharmalabs is headquartered in India. |
| How many employees does Aarti Pharmalabs have? | As of today, Aarti Pharmalabs has over 2K employees. |
| Is Aarti Pharmalabs publicly listed? | Yes, Aarti Pharmalabs is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Aarti Pharmalabs? | Aarti Pharmalabs trades under AARTIPHARM ticker. |
| When did Aarti Pharmalabs go public? | Aarti Pharmalabs went public in 2023. |
| Who are competitors of Aarti Pharmalabs? | Aarti Pharmalabs main competitors are Alkaloid, Zentiva, Guizhou Sanli, Eton Pharmaceuticals. |
| What is the current market cap of Aarti Pharmalabs? | Aarti Pharmalabs' current market cap is $679M. |
| What is the current revenue of Aarti Pharmalabs? | Aarti Pharmalabs' last fiscal year revenue is $223M. |
| What is the current EV/Revenue multiple of Aarti Pharmalabs? | Current revenue multiple of Aarti Pharmalabs is 3.3x. |
| Is Aarti Pharmalabs profitable? | No, Aarti Pharmalabs is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.